Nasdaq confirms Bone Biologics compliance with minimum bid price; one-year panel monitor imposed

Bone Biologics Corp

Received letter from Nasdaq Hearings Advisor on June 28, 2023 confirming compliance with Listing Rule 5550(a)(2) for minimum bid price.
Company subject to Panel Monitor through June 27, 2024; any future non-compliance triggers immediate delisting process with no cure period.
During monitoring, failure to meet any continued listing requirement forfeits standard compliance plan and cure periods, risking delisting.
Company's common stock (BBLG) and warrants (BBLGW) trade on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.